Komen Foundation 1998 Awards Honor Leaders in Fight Against Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 12
Volume 7
Issue 12

DALLAS-More than 2,100 guests attended the Susan G. Komen Foundation’s 16th Annual National Awards luncheon. Candice Bergen, star of the former CBS sitcom, Murphy Brown, received the Foundation’s most prestigious honor-the Betty Ford Award-for her portrayal of the character’s battle with breast cancer during the show’s final season.

DALLAS—More than 2,100 guests attended the Susan G. Komen Foundation’s 16th Annual National Awards luncheon. Candice Bergen, star of the former CBS sitcom, Murphy Brown, received the Foundation’s most prestigious honor—the Betty Ford Award—for her portrayal of the character’s battle with breast cancer during the show’s final season.

Two breast cancer researchers were also honored. Steven E. Harms, MD, professor and director of Imaging Research, University of Arkansas, received the award for Scientific Distinction for developing a minimally invasive laser treatment for small breast cancers. [Look for a report on this research in an upcoming issue of ONI.] Gilbert F. Friedell, MD, director emeritus of the Markey Cancer Center, University of Kentucky, received the award for Individual Community Service for innovative cancer education programs and research.

Articles in this issue
Long-Term Adjuvant Tamoxifen Urged for Low-Risk Breast Cancer
EORTC DCIS Study Confirms Recurrence Reduction With RT
James Cancer Center Joins NCCN Outcomes Database
Managed Care Sees Need for National Guidelines, Accreditation
Advisory Panel Recommends Approval of Vysis HER2 Test
Drinking Tea After Smoking May Reduce Oxidative Stress
Roswell Park and Local HMO Use Claims Data to Study Regional Breast Cancer Care Patterns to Evaluate Quality
Use Special Skills, Tools to Assess Pain in Children, Elderly
Good Response Rates With Radiolabeled Anti-CD20 MoAB in NHL
Tobacco Industry Settles With States
Komen Foundation 1998 Awards Honor Leaders in Fight Against Breast Cancer
Dose Intensity, Density Increased in Breast Cancer
Full FDA Approval for Camptosar
CRFA Presents Frontlines Awards for Breast Cancer Awareness
Panel Recommends FDA Approval of DepoCyt
Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive, HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content

FDA Gives Fast Track Designation to IDE161 for HR+, HER2– Breast Cancer

September 28th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer

September 22nd 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

Neratinib Combo Yields Meaningful Benefit in HR+ HER2-Mutant Breast Cancer

September 18th 2023

FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor

September 7th 2023

FDA Gives Fast Track Designation to IDE161 for HR+, HER2– Breast Cancer

September 28th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer

September 22nd 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

Neratinib Combo Yields Meaningful Benefit in HR+ HER2-Mutant Breast Cancer

September 18th 2023

FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor

September 7th 2023

FDA Gives Fast Track Designation to IDE161 for HR+, HER2– Breast Cancer

September 28th 2023

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023

Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer

September 22nd 2023

Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural Populations

February 27th 2023

Neratinib Combo Yields Meaningful Benefit in HR+ HER2-Mutant Breast Cancer

September 18th 2023

FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor

September 7th 2023